Year in cancer
2000 in cancer
What the index holds for 2000: regulatory decisions dated that year, studies first posted that year, PubMed output per cancer for that year and the registry observations whose reference year it is. Every figure is a count of dated source records — nothing is estimated.
Regulatory
Approval records dated 2000 (22)
Approved, accelerated or conditional records by authority; original applications and records naming one cancer are listed first. One record is one decision for one application or product identifier.
FDA · US: 12 records / 10 drugsHealth Canada · CA: 7 records / 4 drugsEMA · EU: 3 records / 3 drugs
- Sep 25, 2000Arsenic Trioxide FDA · US original application approved Acute Promyelocytic LeukemiaIn combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the…openfda
- Aug 31, 2000Tretinoin FDA · US original application approved Malignant Skin NeoplasmPatients with visible actinic keratosis and patients with a history of skin cancer were excluded from clinical trials of RENOVA (tretinoin cream) 0.02%. Thus…openfda
- Jun 28, 2000Bexarotene FDA · US original application approved Primary Cutaneous T-Cell Non-Hodgkin LymphomaTargretin (bexarotene) gel 1% is indicated for the topical treatment of cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or…openfda
- Jun 15, 2000Triptorelin FDA · US original application approved Malignant Prostate NeoplasmTRELSTAR is indicated for the treatment of advanced prostate cancer [ see Clinical Studies (14) ]. TRELSTAR is a gonadotropin releasing hormone (GnRH) agonist…openfda
- Sep 25, 2000Arsenic Trioxide FDA · US original application approved cancer not stated in this recordFor induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and…openfda
- Aug 31, 2000Tretinoin FDA · US original application approved cancer not stated in this record(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) RENOVA (tretinoin cream) 0.02% is…openfda
- Aug 25, 2000Sirolimus FDA · US original application approved cancer not stated in this record- Patients at low- to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2–4 months after…openfda
- Apr 12, 2000Verteporfin FDA · US original application approved cancer not stated in this recordVISUDYNE ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization…openfda
- Mar 10, 2000Bleomycin FDA · US original application approved cancer not stated in this recordBleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a…openfda
- Jul 13, 2000Doxorubicin EMA · EU centralised approved Malignant Breast NeoplasmMyocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.ema
- Mar 9, 2000Thyrotropin Alfa EMA · EU centralised approved Differentiated Thyroid Gland CarcinomaThyrogen is indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and…ema
- Nov 26, 2000Cyclophosphamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PROCYTOX (DIN 02241797) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
- Oct 26, 2000Cyclophosphamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PROCYTOX (DIN 02241798) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
- Sep 1, 2000Cyclophosphamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PROCYTOX (DIN 02241795) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
- Sep 1, 2000Anastrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2000-09-01 (see label)openfda
- Aug 28, 2000Trastuzumab EMA · EU centralised approved cancer not stated in this recordBreast cancer Metastatic breast cancer Herceptin is indicated for the treatment of patients with HER2-positive metastatic breast cancer: as monotherapy for the…ema
- Aug 22, 2000Cyclophosphamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PROCYTOX (DIN 02241796) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
- Aug 17, 2000Exemestane Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as AROMASIN (DIN 02242705) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
- Apr 20, 2000Irinotecan FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2000-04-20 (see label)openfda
- Apr 4, 2000Dacarbazine Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as DACARBAZINE FOR INJECTION BP (DIN 02241445) under ATC L01AX04 DACARBAZINE. Indications are not published in the Drug Product Database —…health-canada-dpd
- Mar 20, 2000Rituximab Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as RITUXAN (DIN 02241927) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
- Jan 12, 2000Ibuprofen FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2000-01-12 (see label)openfda
RegulatoryAll 2000 records with filters →
Clinical research
Studies first posted in 2000
ClinicalTrials.gov oncology studies whose first-posted date falls in the year (all study types unless stated). Cancer attribution uses reconciled conditions over descendants; one study can count for several top-level cancers.
- Studies
- 62
- Interventional
- 40
- Phase III
- 5
- Industry-led
- 0
- With posted results
- 9
- Countries with sites
- 3
| Phase | Studies | Interventional | Industry share |
|---|---|---|---|
| Phase 1 | 9 | 9 | 0% |
| Phase 2 | 21 | 21 | 0% |
| Phase 3 | 5 | 5 | 0% |
| Not applicable / not stated | 29 | 7 | 0% |
| Cancer | Studies | Phase III |
|---|---|---|
| Non-Hodgkin Lymphoma | 5 | 1 |
| Malignant Breast Neoplasm | 5 | 0 |
| Kaposi Sarcoma | 3 | 0 |
| Malignant Prostate Neoplasm | 3 | 1 |
| Malignant Liver Neoplasm | 2 | 0 |
| Malignant Kidney Neoplasm | 1 | 0 |
| Multiple Myeloma | 1 | 0 |
| Malignant Mesothelioma | 1 | 0 |
| Malignant Central Nervous System Neoplasm | 1 | 0 |
| Malignant Lung Neoplasm | 1 | 0 |
| Leukemia | 1 | 0 |
| Lead sponsor | Class | Studies | Phase III |
|---|---|---|---|
| National Cancer Institute (NCI) | Nih | 13 | 1 |
| National Center for Research Resources (NCRR) | Nih | 11 | 1 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Nih | 2 | 0 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Nih | 2 | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | Nih | 2 | 0 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Nih | 2 | 1 |
| FDA Office of Orphan Products Development | Fed | 2 | 1 |
| University of Texas | Other | 1 | 0 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Nih | 1 | 0 |
| Fairview University Medical Center | Other | 1 | 0 |
Published source: clinicaltrials · first_posted_date as posted